DAY 29:
Compared to the placebo group, there was no significant drop in the viral RNA burden in the molnupiravir group from baseline. (WMD: 0.11; 95% CI; [-0.12, 0.33] p=0.36; I²=0%) (P-value for subgroup differences = 0.04). (Fig 4A)
Overall: The overall pooled analysis of molnupiravir 800mg for mean change in SARS-COV-2 in nasopharyngeal sample from baseline deduce a significant outcome in favour of the interventional drug (WMD: -0.17; 95% CI; [-0.29, 0.33] p=0.003; I²=32%).